UTEK Corporation

Swiss Medica, Inc.

Swiss Medica, Inc.

April 05, 2005 08:30 ET

Swiss Medica, Inc. Acquires Anti-Depression BioHealth Solutions, Inc. From UTEK Corporation; Acquisition Complements Company's Flagship Product





OTC Bulletin Board SYMBOL: SWME

APRIL 5, 2005 - 08:30 ET

Swiss Medica, Inc. Acquires Anti-Depression BioHealth
Solutions, Inc. From UTEK Corporation; Acquisition
Complements Company's Flagship Product

TORONTO & PLANT CITY, Fla.--(CCNMatthews - Apr 5, 2005) -

Swiss Medica, Inc. (OTCBB:SWME), a company that provides innovative
bioscience products, and UTEK Corporation (AMEX:UTK), a leading
technology transfer company, announced today that Swiss Medica has
acquired Anti-Depression BioHealth Solutions, Inc., a subsidiary of UTEK
Corporation, in a cash and stock transaction.

With the acquisition of Anti-Depression BioHealth Solutions, Inc. and
its associated licensed patents: (US Patents 5,612,320, 5,760,014,
Reissue Application No. 09/153,724, US Patent Application 10/158,839,
and Canadian Patent No. 2,179,746), Swiss Medica will be able to
complement its flagship O24 Essential Oil Pain Neutralizer with an
additional product that is both clinically tested and all-natural for
the over-the-counter marketplace. Among other assets, Anti-Depression
BioHealth Solutions, Inc. contains a product that is clinically proven,
when used as directed, to impact mood by working naturally with the body
to raise serotonin levels in the brain.

"Swiss Medica is delighted to pursue this opportunity in the
anti-depressant market," announced Swiss Medica's CEO Raghu Kilambi.
According to Kilambi, "The World Health Organization predicts that
depression may become the second leading cause of disability in 2020
after heart disease. Currently it is the fourth most significant cause
of disability affecting more than 120 million people worldwide.

"I am also pleased that this acquisition will result in total
shareholder dilution of only approximately 3%," added Kilambi.

"UTEK is pleased to consummate this technology transfer with Swiss
Medica, Inc. We look forward to continuing our efforts to identify
additional technology acquisition opportunities for their
consideration," said Joel Edelson, Vice President of UTEK.

About Swiss Medica Inc.

Swiss Medica commercializes proprietary bioscience products that relieve
chronic ailments. We increase our market share through focused
distribution strategies in multiple sales channels. Swiss Medica's
mission is to be a world leader in the commercialization of life
enhancing bioscience products that improve quality of lives. Please
visit our websites at http://www.swissmedica.com and

Swiss Medica's flagship product, the O24™ Essential Oil Pain
Neutralizer, holds US Patent #6,444,238B1. The O24™ pain relief
solution has been used, recommended and praised for its fast-acting and
long-lasting benefits by healthcare professionals in the United States,
Canada and in Europe. O24 is widely available throughout Canada in
leading pharmacies and natural food stores. It is currently sold in an
increasing number of pharmacies throughout the United States. Customers
can also visit http://www.O24zone.com, for ordering details and store
locators for the nearest pharmacy.

About UTEK Corporation

UTEK is a leading, market-driven technology transfer company that
enables companies to rapidly acquire innovative technologies from
universities and research laboratories. UTEK facilitates the
identification and acquisition of external technologies for clients
internationally in exchange for their equity securities, while allowing
research institutions to receive 100% of the royalties. This unique
process is called U2B®. UTEK transfers proprietary technologies with
potential commercial applications to companies seeking product
differentiation resulting in a strategic marketplace advantage. UTEK is
headquartered in Plant City, Florida, USA and has operations in the UK
and Israel. For more information about UTEK, please visit its website at

Forward-Looking Statements

Certain matters discussed in this press release are "forward-looking
statements." These forward-looking statements can generally be
identified as such because the context of the statement will include
words, such as "expects," "should," "believes," "anticipates" or words
of similar import. Similarly, statements that describe future plans,
objectives or goals are also forward-looking statements. Such
forward-looking statements are subject to certain risks and
uncertainties, including the financial performance of UTEK or Swiss
Medica, as appropriate, and the valuation of UTEK's investment
portfolio, which could cause actual results to differ materially from
those currently anticipated. Although UTEK and Swiss Medica believe the
expectations reflected in any forward-looking statements are based on
reasonable assumptions, they cannot give any assurance that their
expectations will be attained. Shareholders, potential investors and
other readers are urged to consider these factors carefully in
evaluating any forward-looking statements. Certain factors could cause
results and conditions to differ materially from those projected in
these forward-looking statements, and some of these factors are
discussed below. These factors are not exhaustive. New factors, risks
and uncertainties may emerge from time to time that may affect the
forward-looking statements made herein. These forward-looking statements
are only made as of the date of this press release and both UTEK and
Swiss Medica do not undertake any obligation to publicly update such
forward-looking statements to reflect subsequent events or circumstances.


Contact Information

    For Swiss Medica, Inc., Toronto
    Blue Skye PR, Inc.
    Sky Wallen, 813-732-6869
    For UTEK Corporation
    Porter LeVay & Rose
    Michael Porter, 212-564-4700
    Steve Liebmann or Susan Scott, +44 20-7444-4140